Login / Signup

What do we have that is new in antifungal peptides? A patent review.

Paula Vz BareñoLeonardo C XavierAnamaria Mendonça SantosLuana RossatoJuliana C da CostaMairim Russo SerafiniDiana Ma NovoaRicardo B SoutoIzabel Almeida Alves
Published in: Future microbiology (2022)
Drugs used to fight fungal infections may cause toxic or adverse drug interactions. For this reason, there is an increase in the development of natural, semisynthetic and synthetic antifungal peptides. This study aimed to perform a patent review to identify the advances in peptides to treat fungal infections. In a preliminary assessment, 597 patents were identified from the database. Then, duplicated patents (62) and those with titles in disagreement with the scope of this review (196) were excluded. Then, six patents were not in English or Spanish. Following the screening, 288 patents were outside the focus of this review, according to their abstract and description. The final selection covered 45 patents.
Keyphrases
  • adverse drug
  • candida albicans
  • amino acid